Page 2 - Michael Halstead News Today

Polar Capital Holdings Plc increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 150.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,000,000 shares of the biopharmaceutical company’s stock after buying an additional 600,000 shares during the quarter. […]

Polar Capital Holdings Plc lifted its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 150.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,000,000 shares of the biopharmaceutical company’s stock after purchasing an additional 600,000 shares during the quarter. Polar Capital Holdings […]

Michael Halstead, EVP and General Counsel of Intra-Cellular Therapies Inc (NASDAQ:ITCI), has sold 7,907 shares of the company on February 26, 2024, according to a recent SEC Filing.

Profund Advisors LLC grew its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 10.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,132 shares of the biopharmaceutical company’s stock after acquiring an additional 1,135 shares during the period. Profund Advisors LLC’s holdings […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.14, Briefing.com reports. Intra-Cellular Therapies had a negative return on equity of 22.83% and a negative net margin of 30.08%. The company had […]

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.14, Briefing.com reports. Intra-Cellular Therapies had a negative return on equity of 22.83% and a negative net margin of 30.08%. The business […]

Clearbridge Investments LLC trimmed its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 0.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,403,601 shares of the biopharmaceutical company’s stock after selling 10,144 shares during the period. Clearbridge Investments LLC’s holdings in Intra-Cellular Therapies […]

Healthcare of Ontario Pension Plan Trust Fund raised its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 209.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 154,700 shares of the biopharmaceutical company’s stock after buying an additional 104,700 shares […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report)’s stock price hit a new 52-week high during trading on Thursday . The company traded as high as $74.33 and last traded at $74.03, with a volume of 496623 shares traded. The stock had previously closed at $71.99. Analysts Set New Price Targets A number of brokerages […]

Headlands Technologies LLC boosted its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 96.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,027 shares of the biopharmaceutical company’s stock after buying an additional 1,982 shares during the quarter. Headlands Technologies LLC’s […]